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A commentary on
Potential Links between Hepadnavirus and Bornavirus Sequences in the Host Genome and
Cancer
by Honda, T. (2017). Front. Microbiol. 8:2537. doi: 10.3389/fmicb.2017.02537
In the paper by Honda et al. (Honda, 2017), sequences of non-retroviral RNA viruses seem to
have been integrated into the host genome possibly by machineries of host retrotransposon, long
interspersed nuclear element 1 (LINE-1, or L1). The integration events of viral sequences occur not
only in somatic cells, but also in germ line cells and then can be inherited as EVEs (endogenous viral
elements). Honda reports various possibilities for EVEs to have oncogenic potential and focuses
both on HBV viruses for the occurrence of HCC and on endogenous bornavirus-like elements
(EBLs).
Because EBLs are the only non-retroviral RNA virus-derived EVEs found in the human genome
thus far, Honda focuses on the possible link between these elements and cancer, although the links
have not been demonstrated.
Among the 7 Homo sapiens EBLNs (hsEBLN), hsEBLN-2 is most closely linked to cancer. Gene
ontology analysis concerning EBLN-2 suggests that it might be a tumor suppressor gene (TSG).
Interestingly, because mitochondrial dysfunction is found in cancer, hsHBLN-2 might play
important roles in mitochondrial function and then act as a TSG. Honda correctly states that
“Epidemiologic studies on the links between EBL mutations and cancers are clearly required.
Furthermore, the causal relationship between such EBL mutations and cancers should be
demonstrated in the future.” In particular, Honda quotes extensively one of our papers: “Whole
exome sequencing (WES) using two sibling pairs of non-smokers with lung adenocarcinoma
reveals that a truncated mutation in hsEBLN-2 is only detected in affected siblings (Renieri et al.,
2014). The authors concluded that this mutation in hsEBLN-2 might predispose an individual to
lung adenocarcinoma (ADCA)” (Honda, 2017). We indeed identified a frameshift mutation, the
c.250dupA, p.N83fs in EBLN2 gene (NM_018029) (Renieri et al., 2014). Interestingly, according to
Honda, our report is the only study reporting a germline mutation of hsEBLN-2 associated with
tumor occurrence in the clinical setting.
We would like to make some comments, namely concerning our original approach to oligogenic
signatures (i.e., the germlinemutation of 5–8 genes) in the occurrence of common sporadic tumors.
We have used WES, associated with a discordant sibling strategy, to show that siblings sharing
50% of the genome, could differ for 5–8 germ linemutations, likely facilitating cancer occurrence in
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FIGURE 1 | (A) Modified from Honda (2017). The hsEBLN-2 protein may be
involved in mitochondrial function and might be a tumor suppressor.
(B) EBLN-2 is involved in cancers together with others genes. For example in
our study about lung adenocarcinoma susceptibility we found the involvement
of TAF1b (component of RNA polymerase I core factor complex that acts as a
GTF2B/TFIIB-like factor and plays a key role in multiple steps during
transcription initiation), RBMX (RNA-binding protein that plays several roles in
the regulation of pre- and post-transcriptional processes), ZNF311 (may be
involved in transcriptional regulation), WISP3 (appears to be required for
normal postnatal skeletal growth and cartilage homeostasis, and WISP3
regulates accumulation of cellular reactive oxygen species) as a
proof-of-concept of the oligogenic theory (Renieri et al., 2014).
one sibling and its absence in the other. This is in line with the
modern trend toward “personalized medicine,” i.e., each subject
finds his/her personal way to cancer and every individual cancer
is different from the other.
Therefore, we suggest caution before extrapolating that
EBNL-2, a suspected tumor suppressor gene, could play a
role such as APC germ line mutations in the occurrence of
familial adenomatous polyposis (FAP) (Cetta et al., 2001)—or
of other TSGs as causal responsible for inherited multitumoral
syndromes—, in the occurrence of lung ADCA. EBLN-2 protein
may be involved in regulation of tumor-related genes, in
mitochondrial function and microtubule regulation (Figure 1A).
Honda suggests that this mechanism could act as a pathogenic
factor for the formation of a given tumor, namely lung
adenocarcinoma, maybe according to “conventional” pathogenic
pathways. In our study, on the contrary germ line mutation of the
EBLN gene has been found as a part of an “oligogenic signature”
responsible for tumor occurrence in a discordant sibling model,
that aims at detecting the congenital basis for the emergence of a
“personalized” tumoral variant, according to current knowledge
concerning personalized medicine (Figure 1B).
Our study is based on a philosophy that is completely different
from the “gene hunting” approach of 30 years ago, aimed at
detecting a single gene responsible for a single cancer. Namely, we
have already found a peculiar oligogenic signature, responsible
for lung ADCA in six additional discordant siblings (Cetta et al.,
2017). Interestingly, a total of more than 50 different genes have
been detected as “facilitating germ line mutations” in oncogenes
or TSG in the entire series of eight patients with lung ADCA.
They are responsible for the formation of a “personal” cancer,
even if they could not include the single main determinant of
tumor occurrence. Similar findings have also been detected in
a non-smoker with lung squamous cell carcinoma (Baldassarri
et al., 2018).
We hope that this comment could help to clarify better the
significance of our findings. EBNL2 is not a gene specifically
causing the formation of lung adenocarcinoma, but a germline
mutation that may facilitate its occurrence as a component of
a tumor predisposing oligogenic signature, at individual level.
While waiting for more stringent causal relationships between
EBLN-2 and various types of cancers, we think that the present
clarification could prevent misleading interpretations.
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